Rosetta Biosoftware's Rosetta Syllego System Achieves GeneChip-compatible(TM) Status with the Affymetrix GeneChip(R) Microarray Platform.The Rosetta Syllego System Version 1.0 Will Be Showcased at the 57(th) Annual Meeting of the American Society for Human Genetics Human genetics A discipline concerned with genetically determined resemblances and differences among human beings. Technological advances in the visualization of human chromosomes have shown that abnormalities of chromosome number or structure are surprisingly Conference in San Diego San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. , Calif., October 23-27 SEATTLE -- Rosetta Biosoftware, a leader in life science informatics solutions, today announced that the Rosetta Syllego[TM] system has achieved GeneChip-compatible(TM) status for use with the Affymetrix microarray platform. This compatibility enables research organizations conducting genome-wide association and other genetic studies to focus on revealing genetic risk factors and therapies for diseases, such as coronary artery disease coronary artery disease, condition that results when the coronary arteries are narrowed or occluded, most commonly by atherosclerotic deposits of fibrous and fatty tissue. , type 2 diabetes type 2 diabetes n. See diabetes mellitus. , and other complex diseases. Genetic studies of complex diseases and traits pose a number of informatics challenges that impede the accurate and reproducible identification of genetic markers of disease and drug response. Through the Affymetrix GeneChip Compatible Program, Affymetrix collaborates with software developers like Rosetta Biosoftware by providing software development tools and guidelines to conquer many of these challenges. The Rosetta Syllego system overcomes the informatics challenges of genetic studies by providing biologists, statistical geneticists This is a list of people who have made notable contributions to genetics. The growth and development of genetics represents the work of many people. This list of geneticists is therefore by no means complete. Contributors of great distinction to genetics are not yet on the list. , and investigators responsible for generating genotyping data with tools for data management, quality control, data analysis, and meta-analysis. The Syllego system brings together genotyping data generated by Affymetrix and other microarray platforms, tools for linking to analysis methods of choice, and easy-to-use project workspaces to organize, analyze, and share data and analysis results. The Syllego system is also a single repository for fast, easy access to public and private genotyping data sets, reference annotation, and non-clinical and clinical information. "Genetic studies often generate vast quantities of data, in which lie the keys to understanding the hereditary basis of disease," says Steve Lincoln, Vice President of Informatics of Affymetrix. "The data management and analysis capabilities of the Syllego system allow researchers to focus on their science and make discoveries using these new paradigms in genetic research." "What sets the Syllego system apart is its remarkable ability to bring together groups of geneticists, biologists, and informaticians through the use of a single genotyping data repository See repository. ," says Yelena Shevelenko, Vice President and General Manger of Rosetta Biosoftware. "By bringing scientists and data together through the Syllego system, we are helping the research community to reduce costs, accelerate discovery, and focus on the science behind genetic studies." The Syllego system supports the latest Affymetrix Genome-wide Human SNP Array In molecular biology and bioinformatics, a SNP array is a type of DNA microarray which is used to detect polymorphisms within a population. A single nucleotide polymorphism (SNP), a variation at a single site in DNA, is the most frequent type of variation in the genome. 6.0 and includes data analysis tools along with the ability to integrate study data with common statistical packages, such as R. The commercial version 1.0 of the Syllego system will be showcased at a workshop at the upcoming 57th annual meeting of the American Society for Human Genetics conference in San Diego, Calif., on October 24. To evaluate the Syllego system, interested parties can request a copy at: www.rosettabio.com/products/syllego/trial. About the Rosetta Syllego System The Rosetta Syllego system is Rosetta Biosoftware's practical solution for genetic data management and analysis. For more information on the Syllego system, please visit www.rosettabio.com/syllego. About Rosetta Biosoftware Rosetta Biosoftware is a leading provider of informatics solutions for life science research. Its comprehensive software solutions, including the Rosetta Resolver, Rosetta Elucidator, and Rosetta Syllego systems, empower life scientists with advanced, scalable, and easy-to-use analysis platforms that accelerate discovery research. Rosetta Biosoftware is a business unit of Rosetta Inpharmatics LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control , a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of Merck & Co., Inc. (NYSE NYSE See: New York Stock Exchange :MRK MRK Merck & Company (stock symbol) MRK Mayer-Rokitansky-Kuster (anomaly) MRK Manual Remote Keying ). More information about Rosetta Biosoftware is available at www.rosettabio.com. About the Affymetrix Developers' Network (ADN ADN Anchorage Daily News (Alaska newspaper) ADN Yemen (international vehicle registration) ADN Ácido Desoxirribonucleico ADN Acide Désoxyribonucléique (French: DNA) ) Through one of the largest third-party software developer communities within the life science industry, Affymetrix works with its software developers to provide a broad spectrum of solutions for leveraging gene expression and genetic variation analysis in both biomedical research Biomedical research (or experimental medicine), in general simply known as medical research, is the basic research or applied research conducted to aid the body of knowledge in the field of medicine. and development. Membership in ADN is free of charge for both commercial and academic software developers. For more information please visit www.affymetrix.com/genechip/developer. View the GeneChip-compatible Software Solutions Catalog at www.affymetrix.com/genechip/compatible. About Affymetrix Affymetrix GeneChip([R]) microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more complete view of the genome. These products continue to accelerate genetic research and enable scientists to develop diagnostics and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases. Today, Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. , as well as leading academic, government and not-for-profit research institutes. More than 1,600 systems have been shipped around the world and more than 9,500 peer-reviewed papers have been published using the technology. Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Sacramento, Calif., and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit: www.affymetrix.com. Forward-Looking Statements This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Neither Rosetta Inpharmatics nor Merck & Co., Inc. undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect the business of Merck & Co., Inc. including, among others, the extent to which Rosetta Inpharmatics' technology platform can be used in drug discovery programs, uncertainty of market acceptance of Rosetta Inpharmatics' technologies, ability to compete against existing technologies, and those mentioned in the cautionary statements in Item 1 of Merck's Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended Dec. 31, 2006, and in its periodic reports on Form 10-Q Form 10-Q See 10-Q. and Form 8-K Form 8-K The form required by the SEC when a publicly held company incurs any event that might affect its financial situation or the share value of its stock. Form 8-K See 8-K. (if any) which are incorporated by reference. Affymetrix, the Affymetrix logo and GeneChip[R] are registered trademarks of Affymetrix, Inc. Rosetta Syllego and Syllego are trademarks of Rosetta Inpharmatics LLC. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion